LOW-VOLUME · FEMALE-LED
norethindrone Side Effects
norethindrone (also sold as Camila, Errin) is a LOW-VOLUME FAERS extract #389 of 524 by FAERS report count. Still opens on FEMALE-LED: 99% of sex-coded reports are female (4,688 F / 40 M).
Data updated 2026-05-15
- 5,342
- FAERS reports
Thinner FAERS book - still a temporal association ledger, not proof of cause. Methodology.
norethindrone reporting skew - 99% of sex-coded reports are female (4,688 F / 40 M). Volume band LOW-VOLUME #389 of 524 by FAERS report count; caseload WATCHLIST.
Thinner FAERS extract for norethindrone (Camila) (5,342 reports #389 of 524 by FAERS report count). 99% of sex-coded reports are female (4,688 F / 40 M). Sparse books still carry named reaction rows when present; not medical advice.
Counts from the openFDA FAERS extract (2004–2025). Stamps WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
NAUSEA leads 449 of 5,342 reports
FEMALE-LED reporters · age peak 18-44
Female-led reporters (99% of sex-coded rows)
Age peak 18-44 (2,242 reports)
FAERS filings rising toward 2025
Reactions in Death Reports
Death appears on 80 reports (1.5% - MARKED). Reactions below co-occur in those rows only.
| Reaction | Reports |
|---|---|
| DEATH | 22 |
| PNEUMONIA | 11 |
| RESPIRATORY FAILURE | 10 |
| CARDIAC ARREST | 7 |
| DYSPNOEA | 6 |
| GENERAL PHYSICAL HEALTH DETERIORATION | 5 |
| HYPERTENSION | 5 |
| PAIN | 5 |
| RENAL FAILURE | 5 |
| ACUTE KIDNEY INJURY | 4 |
| BREAST CANCER METASTATIC | 4 |
| INTENTIONAL PRODUCT MISUSE | 4 |
| LUNG DISORDER | 4 |
| MALIGNANT NEOPLASM PROGRESSION | 4 |
| NAUSEA | 4 |
| PANCREATITIS | 4 |
| PULMONARY FIBROSIS | 4 |
| VOMITING | 4 |
Reactions in Hospitalization Reports
Hospitalization mid-share (945, 17.7%). Co-reported reactions:
| Reaction | Reports |
|---|---|
| HEADACHE | 85 |
| NAUSEA | 82 |
| PAIN | 77 |
| DYSPNOEA | 76 |
| VOMITING | 68 |
| ABDOMINAL PAIN | 63 |
| FATIGUE | 61 |
| DIARRHOEA | 55 |
| PYREXIA | 55 |
| PULMONARY EMBOLISM | 50 |
| ARTHRALGIA | 45 |
| VAGINAL HAEMORRHAGE | 45 |
| MALAISE | 44 |
| ANXIETY | 43 |
| HAEMOGLOBIN DECREASED | 41 |
| MIGRAINE | 38 |
| DIZZINESS | 37 |
| HYPERTENSION | 37 |
How to read norethindrone FAERS figures (WATCHLIST · DEATH-MARKED · HOSP-MID)
FAERS holds 5,342 voluntary reports linked to norethindrone (Camila, Errin), 2004-2025. Death is listed on 80 (1.5%). Hospitalization appears on 945 (17.7%). Top co-reported indication: Product Used For Unknown Indication.
Sparse extract - named reactions and FEMALE-LED skew still differ by drug; not a complete safety profile.
Read with norethindrone
Peers ranked by ABS(total_reports), then an ABS(death_share) pole; guide hop follows DEATH-MARKED · HOSP-MID stamps.
ABS(total_reports) peer at 5,230 FAERS cases (Δ 112 lighter vs norethindrone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 5,225 FAERS cases (Δ 117 lighter vs norethindrone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 5,460 FAERS cases (Δ 118 heavier vs norethindrone); DEATH-MARKED · HOSP-MID · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(total_reports) peer at 5,207 FAERS cases (Δ 135 lighter vs norethindrone); DEATH-HEAVY · HOSP-HEAVY · SEX-BALANCED vs this page's WATCHLIST · DEATH-MARKED · HOSP-MID · FEMALE-LED.
ABS(death_share) pole at 62.1% death-mentioned reports (Δ 60.6 pp vs norethindrone's DEATH-MARKED): CASELOAD · HOSP-MID.
norethindrone stamps WATCHLIST · FEMALE-LED; class peers and methodology beat restating the same FAERS caveats on every effects URL.